InMed Pharmaceuticals Inc. INM

Company Overview

InMed Pharmaceuticals Inc. is a Canadian biotechnology and pharmaceutical development company focused on the research, development, and commercialization of cannabinoid-based therapeutics. The company operates primarily in the biotechnology, specialty pharmaceuticals, and cannabinoid science industries, with activities centered on rare diseases, pharmaceutical manufacturing technologies, and cannabinoid biosynthesis. InMed’s core business model combines proprietary cannabinoid research with drug development programs and manufacturing capabilities intended to support both pharmaceutical and health-related commercial applications.

The company’s primary revenue and strategic focus have historically been tied to research and development initiatives, intellectual property generation, and partnerships related to cannabinoid technologies. Through its subsidiary BayMedica LLC, InMed expanded into the commercial manufacturing and distribution of rare cannabinoids for health and wellness markets. The company traces its origins to cannabinoid research initiatives developed in Canada and later evolved through acquisitions and technology expansion into biosynthesis and large-scale cannabinoid production. Its strategic positioning is based on proprietary cannabinoid manufacturing capabilities, specialized expertise in rare cannabinoids, and an integrated approach spanning pharmaceutical research and commercial cannabinoid ingredient supply.